Glucose Monitoring Use Has Grown Among Type 2 Patients
A new report shows many people with Type 2 diabetes use CGM to manage their health, though barriers to access remain.
Updated on Sept. 28, 2026 in Diabetes
Live Poll
Do you believe constant digital health monitoring helps you better manage your daily health decisions?
Dexcom has released its 2026 State of Type 2 Report, which identifies shifting trends in how patients monitor their glucose levels. The survey of 3,300 people across eight countries highlights both the increasing independence users feel with technology and the hurdles they face regarding insurance coverage.
Why it matters
Understanding these adoption trends is critical because continuous glucose monitoring (CGM) is increasingly being used alongside GLP-1 medications to better manage blood sugar. The report highlights that while patients see value in these tools, widespread access is still hindered by financial and reimbursement challenges.
A survey of 800 healthcare professionals and 2,500 people with Type 2 diabetes across eight countries indicates that 89% of providers believe CGM improves adherence. While 94% of users report better independent management, 55% of patients still report limited knowledge of the technology.
The players
Dexcom
A medical device company that produces continuous glucose monitoring technology for diabetes management.
Team Novo Nordisk
An all-diabetes professional cycling team that serves as a global advocate for people living with the condition.
The details
Continuous glucose monitoring systems function by using a small sensor to provide real-time, objective data on blood glucose levels throughout the day and night. By offering immediate feedback, these devices help patients and providers understand how specific meals, physical activity, and medications like GLP-1s influence blood sugar regulation. This high-frequency data helps shift diabetes care from reactive adjustments to proactive, evidence-based management.
Timeline
The 2026 State of Type 2 Report was released on September 28, 2026.
The findings were presented during the EASD meeting held from September 28, 2026, to October 2, 2026.
Health Landscape
The findings presented at the EASD annual meeting reflect the growing integration of digital health tools in standard diabetes treatment protocols. This marks a significant shift as clinical practice moves toward data-driven, personalized care for patients using GLP-1 therapies.
If you are managing Type 2 diabetes, you may want to ask your doctor if continuous glucose monitoring could provide helpful insights into how your diet or medications affect your levels. It is also worth discussing whether your current insurance plan covers these systems to address common access barriers.
The takeaway
The use of glucose monitoring technology can help you gain a clearer picture of your blood sugar patterns throughout the day. Discuss with your physician whether integrating this data into your treatment plan—especially if you are currently using GLP-1 medications—is appropriate for your care.
Further reading
For more information on managing your care, visit the Diabetes section.
More information
Read the full Dexcom State of Type 2 Report for more data on current trends.
Live Poll
Do you believe constant digital health monitoring helps you better manage your daily health decisions?
